Cashing in on the Future

As a university faculty member, you helped develop a technology that was licensed to industry. As part of the deal, you were given a share of the royalties from future products. The future is here, and the royalty checks may not be rolling in--or if they are coming in, they're not enough to fund your life's dream. Perhaps you should consider doing what companies, universities, and more and more individuals are doing: in the words of Walter Flamenbaum, a partner in Paul Capital Partners in New Yo

| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

As a university faculty member, you helped develop a technology that was licensed to industry. As part of the deal, you were given a share of the royalties from future products. The future is here, and the royalty checks may not be rolling in--or if they are coming in, they're not enough to fund your life's dream. Perhaps you should consider doing what companies, universities, and more and more individuals are doing: in the words of Walter Flamenbaum, a partner in Paul Capital Partners in New York, "monetization, taking an asset and turning it into money."

In the strictest sense, this method will "monetize" a "royalty stream," as the term is used by David Robinson, chairman and CEO of Ligand Pharmaceuticals in San Diego, a company that has taken advantage of this method to bring in cash. In other words, this is the sale of royalties--in these cases, to a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Myrna Watanabe

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo